Anaplastic Lymphoma Kinase in Cutaneous Malignancies

DSpace/Manakin Repository

Anaplastic Lymphoma Kinase in Cutaneous Malignancies

Citable link to this page

 

 
Title: Anaplastic Lymphoma Kinase in Cutaneous Malignancies
Author: Cao, Severine; Nambudiri, Vinod E.

Note: Order does not necessarily reflect citation order of authors.

Citation: Cao, Severine, and Vinod E. Nambudiri. 2017. “Anaplastic Lymphoma Kinase in Cutaneous Malignancies.” Cancers 9 (9): 123. doi:10.3390/cancers9090123. http://dx.doi.org/10.3390/cancers9090123.
Full Text & Related Files:
Abstract: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been implicated in the pathogenesis of a variety of neoplasms. As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic ALK mutations subsequently coming to attention in the development of many other hematologic and solid organ malignancies. ALK has now been shown to play a role in the pathogenesis of several cutaneous malignancies, including secondary cutaneous systemic anaplastic large-cell lymphoma (ALCL) and primary cutaneous ALCL, melanoma, spitzoid tumors, epithelioid fibrous histiocytoma, Merkel cell carcinoma, and basal cell carcinoma. The characterization of ALK-positivity in these cutaneous malignancies presents exciting opportunities for utilizing ALK-targeted inhibitors in the treatment of these diseases.
Published Version: doi:10.3390/cancers9090123
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615338/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492019
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters